GSK

Shingrix is a non-live, recombinant subunit vaccine to be given intramuscularly in two doses for the prevention of shingles…

There is currently no vaccine for the virus in adults. Moderna, Pfizer and GSK are racing to get their RSV vaccines to market…

WuXi Biologics will receive a $40 million upfront payment and up to $1.46 billion in additional payments for research,…

The snub caused Valneva's shares to fall, with Valneva down by around one per cent during the late morning trading session in…

While the companies, which have all marketed the drug at different times, still face tens of thousands of similar lawsuits in…

The company had said this month that Blenrep had failed the main goal of a key study designed to show it was better than an…

In a late-stage study, the antibody-based drug, otilimab, did not make a meaningful difference to improving swelling and…

GSK plans to bring Shingrix to India in 2023

The trial, which involved roughly 25,000 adults aged 60 years and more, tested a single dose of the experimental vaccine against a…

Zantac, originally marketed by a forerunner of GSK, has been sold by several companies at different times, including Pfizer,…